Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug; Novo to test Wegovy and other obesity drugs against alcohol-related liver disease

Taking stock of the drug industry, from the lab to the medicine chest

May 14, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Ric Francis/AP STAT+ | Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug "The decision not to pursue [a lower dose] comes at a significant cost to patients and American taxpayers," Sen. Dick Durbin wrote Amgen. By Ed Silverman STAT+ | Novo to test Wegovy and other obesity drugs against alcohol-related liver disease The company will see if it can expand its weight loss drugs into yet another significant area, that of harms from alcohol consumption. By Isabella Cueto and Elaine Chen STAT+ | Cue Health's Covid-19 tests could give false results, FDA warns FDA warned consumers against using Cue Health's Covid-19 tests as it might lead to false results. By Brittany Trang Element Biosciences STAT+ | Element Biosciences, an Illumina rival, on its genomics ambitions — and why it hasn't gone public QA with Molly He: Element is betting its blend of accuracy and moderate price point can help it carve out a niche of academic and biopharma customers. By Jonathan Wosen

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser